Irene Leung1,2, Ferenc B Sallo3, Roberto Bonelli4,5, Traci E Clemons6, Daniel Pauleikhoff7, Emily Y Chew8, Alan C Bird9, Tunde Peto10. 1. Department of Research and Development, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom. 2. NIHR Biomedical Research Center for Ophthalmology at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom. 3. UCL Institute of Ophthalmology, London, United Kingdom. 4. Population Health and Immunity, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. 5. Department of Medical Biology, The University of Melbourne, Melbourne, Australia. 6. The EMMES Corporation, Rockville, Maryland. 7. Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany. 8. National Eye Institute, National Institutes of Health, Bethesda, Maryland. 9. Inherited Eye Disease, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom. 10. Department of Ophthalmology, Queen's University Belfast Faculty of Medicine, Health and Life Sciences, Belfast, United Kingdom.
Abstract
PURPOSE: Pigment in the midretina is a characteristic sign in Type 2 idiopathic macular telangiectasia (MacTel) and is considered to characterize the late stage of the disease. Our aim was to investigate its incidence, and relationship with risk factors for MacTel, including outer retinal vascularization and subretinal neovascular proliferation (SRNV). METHODS: Pigment extent was measured in fundus autofluorescence images of 150 eyes of 75 MacTel probands, using the Region Finder tool of Heidelberg Eye Explorer. A linear mixed model was used to analyze the dynamics of pigment and its associations with other features of the phenotype. The relative incidence of pigment and of outer retinal outer retinal vascularization and SRNV was analyzed within the full MacTel Study cohort (1,244 probands). RESULTS: Mean pigment area at baseline was 0.157 mm (range = 0-1.295 mm, SD = 0.228 mm, n = 101). Progression demonstrated a nonlinear pattern (P < 0.001) at an overall rate of 0.0177 mm/year and was associated with the initial plaque size and with SRNV. There was a strong correlation between fellow eyes (P ≤ 0.0001). In approximately 25% of all SRNV cases, SRNV may coincide with or precede pigment. CONCLUSION: Our data may be useful for refining the current system for staging disease severity in MacTel.
PURPOSE: Pigment in the midretina is a characteristic sign in Type 2 idiopathic macular telangiectasia (MacTel) and is considered to characterize the late stage of the disease. Our aim was to investigate its incidence, and relationship with risk factors for MacTel, including outer retinal vascularization and subretinal neovascular proliferation (SRNV). METHODS: Pigment extent was measured in fundus autofluorescence images of 150 eyes of 75 MacTel probands, using the Region Finder tool of Heidelberg Eye Explorer. A linear mixed model was used to analyze the dynamics of pigment and its associations with other features of the phenotype. The relative incidence of pigment and of outer retinal outer retinal vascularization and SRNV was analyzed within the full MacTel Study cohort (1,244 probands). RESULTS: Mean pigment area at baseline was 0.157 mm (range = 0-1.295 mm, SD = 0.228 mm, n = 101). Progression demonstrated a nonlinear pattern (P < 0.001) at an overall rate of 0.0177 mm/year and was associated with the initial plaque size and with SRNV. There was a strong correlation between fellow eyes (P ≤ 0.0001). In approximately 25% of all SRNV cases, SRNV may coincide with or precede pigment. CONCLUSION: Our data may be useful for refining the current system for staging disease severity in MacTel.
Authors: Michael I Dorrell; Edith Aguilar; Ruth Jacobson; Oscar Yanes; Ray Gariano; John Heckenlively; Eyal Banin; G Anthony Ramirez; Mehdi Gasmi; Alan Bird; Gary Siuzdak; Martin Friedlander Journal: J Clin Invest Date: 2009-02-02 Impact factor: 14.808
Authors: Wai T Wong; Farzin Forooghian; Zigurts Majumdar; Robert F Bonner; Denise Cunningham; Emily Y Chew Journal: Am J Ophthalmol Date: 2009-07-02 Impact factor: 5.258
Authors: Peter Charbel Issa; Tos T J M Berendschot; Giovanni Staurenghi; Frank G Holz; Hendrik P N Scholl Journal: Invest Ophthalmol Vis Sci Date: 2008-03 Impact factor: 4.799
Authors: Weiyong Shen; Marcus Fruttiger; Ling Zhu; Sook H Chung; Nigel L Barnett; Joshua K Kirk; SoRa Lee; Nathan J Coorey; Murray Killingsworth; Larry S Sherman; Mark C Gillies Journal: J Neurosci Date: 2012-11-07 Impact factor: 6.167
Authors: Laura Kuehlewein; Amir H Hariri; Alexander Ho; Laurie Dustin; Yulia Wolfson; Rupert W Strauss; Hendrik P N Scholl; SriniVas R Sadda Journal: Retina Date: 2016-06 Impact factor: 4.256
Authors: Traci E Clemons; Marc C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Maria J Figueroa; Molly W Harrington Journal: Ophthalmic Epidemiol Date: 2010 Jan-Feb Impact factor: 1.648
Authors: Jean-Sébastien Joyal; Ye Sun; Marin L Gantner; Zhuo Shao; Lucy P Evans; Nicholas Saba; Thomas Fredrick; Samuel Burnim; Jin Sung Kim; Gauri Patel; Aimee M Juan; Christian G Hurst; Colman J Hatton; Zhenghao Cui; Kerry A Pierce; Patrick Bherer; Edith Aguilar; Michael B Powner; Kristis Vevis; Michel Boisvert; Zhongjie Fu; Emile Levy; Marcus Fruttiger; Alan Packard; Flavio A Rezende; Bruno Maranda; Przemyslaw Sapieha; Jing Chen; Martin Friedlander; Clary B Clish; Lois E H Smith Journal: Nat Med Date: 2016-03-14 Impact factor: 53.440
Authors: Daniel Pauleikhoff; Roberto Bonelli; Adam M Dubis; Frederic Gunnemann; Kai Rothaus; Peter Charbel Issa; Tjebo Fc Heeren; Tunde Peto; Traci E Clemons; Emily Y Chew; Alan C Bird; Ferenc B Sallo Journal: Acta Ophthalmol Date: 2019-04-09 Impact factor: 3.761
Authors: Charles L Zucker; Paul S Bernstein; Richard L Schalek; Jeff W Lichtman; John E Dowling Journal: Proc Natl Acad Sci U S A Date: 2020-07-22 Impact factor: 11.205